UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE
<p>Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by education activity directed to doctors...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-12-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | http://www.rpcardio.ru/jour/article/view/540 |
| _version_ | 1827854201087066112 |
|---|---|
| author | S. Yu. Martsevich V. P. Voronina M. L. Ginzburg N. P. Kutishenko Yu. N. Polyanskaya T. G. Kheliya A. M. Malysheva S. N. Tolpygina V. S. Kutuzova E. A. Gofman A. D. Deev |
| author_facet | S. Yu. Martsevich V. P. Voronina M. L. Ginzburg N. P. Kutishenko Yu. N. Polyanskaya T. G. Kheliya A. M. Malysheva S. N. Tolpygina V. S. Kutuzova E. A. Gofman A. D. Deev |
| author_sort | S. Yu. Martsevich |
| collection | DOAJ |
| description | <p>Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by education activity directed to doctors. Material and methods. The study consisted of 3 parts. Parts I and II present the results of two questionnaire surveys of patients with acute myocardial infarction, or stenting, who needed in DAT according to current clinical guidelines. The real use of the DAT was assessed in part III on the basis of the multicenter study conducted in different regions of Russia (ROMB study) in a large sample of patients having DAT indications. Results. Part I - PROGNOZ-IBS study. According to the questionnaire survey only 112 out of 239 patients (47%) having an absolute indications, received DOT. Part II - phone survey of patients with acute myocardial infarction in two towns of Lyubertsy and Podolsk. 28 of 71 patients (39%) took the DAT (from some days to 6 months) and 35 patients (49%) — did not take it. Part III - ROMB study. 519 patients did not take DAT, at that 259 (50%) in hospital and 260 (50%) - in out-patient clinic. 521 patients took DAT according to indications, at that 238 (46%) in hospital and 283 (54%) - in out-patient clinic. Conclusion. Less than 50% of patients, having direct indications, received DAT in the real clinical practice. The prescription rate can be improved due to education activity directed to doctors and increase in clopidogrel drugs affordability.</p> |
| first_indexed | 2024-03-12T11:17:07Z |
| format | Article |
| id | doaj.art-d4842d36dd064b1cbe576ea1ce372187 |
| institution | Directory Open Access Journal |
| issn | 1819-6446 2225-3653 |
| language | English |
| last_indexed | 2024-03-12T11:17:07Z |
| publishDate | 2015-12-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj.art-d4842d36dd064b1cbe576ea1ce3721872023-09-02T01:50:31ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-12-018216316710.1234/1819-6446-2012-2-163-167540UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICES. Yu. Martsevich0V. P. Voronina1M. L. Ginzburg2N. P. Kutishenko3Yu. N. Polyanskaya4T. G. Kheliya5A. M. Malysheva6S. N. Tolpygina7V. S. Kutuzova8E. A. Gofman9A. D. Deev10Государственный научно-исследовательский центр профилактической медицины Первый Московский Государственный Медицинский Университет им. СеченоваГосударственный научно-исследовательский центр профилактической медициныГосударственный научно-исследовательский центр профилактической медицины Люберецкая районная больница №2Государственный научно-исследовательский центр профилактической медицины Первый Московский Государственный Медицинский Университет им. СеченоваГосударственный научно-исследовательский центр профилактической медициныГосударственный научно-исследовательский центр профилактической медициныГосударственный научно-исследовательский центр профилактической медициныГосударственный научно-исследовательский центр профилактической медициныПодольская Городская Клиническая больницаГосударственный научно-исследовательский центр профилактической медициныГосударственный научно-исследовательский центр профилактической медицины<p>Aim. To assess the real rate of dual antiplatelet therapy (DAT, acetylsalicylic acid + clopidogrel) use in patients having appropriate indications according to current clinical guidelines and to study the possibility of prescription rate improvement by education activity directed to doctors. Material and methods. The study consisted of 3 parts. Parts I and II present the results of two questionnaire surveys of patients with acute myocardial infarction, or stenting, who needed in DAT according to current clinical guidelines. The real use of the DAT was assessed in part III on the basis of the multicenter study conducted in different regions of Russia (ROMB study) in a large sample of patients having DAT indications. Results. Part I - PROGNOZ-IBS study. According to the questionnaire survey only 112 out of 239 patients (47%) having an absolute indications, received DOT. Part II - phone survey of patients with acute myocardial infarction in two towns of Lyubertsy and Podolsk. 28 of 71 patients (39%) took the DAT (from some days to 6 months) and 35 patients (49%) — did not take it. Part III - ROMB study. 519 patients did not take DAT, at that 259 (50%) in hospital and 260 (50%) - in out-patient clinic. 521 patients took DAT according to indications, at that 238 (46%) in hospital and 283 (54%) - in out-patient clinic. Conclusion. Less than 50% of patients, having direct indications, received DAT in the real clinical practice. The prescription rate can be improved due to education activity directed to doctors and increase in clopidogrel drugs affordability.</p>http://www.rpcardio.ru/jour/article/view/540антиагрегантыклопидогрелоригинальный лекарственный препаратвоспроизведенный лекарственный препаратдвойная антиагрегантная терапия |
| spellingShingle | S. Yu. Martsevich V. P. Voronina M. L. Ginzburg N. P. Kutishenko Yu. N. Polyanskaya T. G. Kheliya A. M. Malysheva S. N. Tolpygina V. S. Kutuzova E. A. Gofman A. D. Deev UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE Рациональная фармакотерапия в кардиологии антиагреганты клопидогрел оригинальный лекарственный препарат воспроизведенный лекарственный препарат двойная антиагрегантная терапия |
| title | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE |
| title_full | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE |
| title_fullStr | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE |
| title_full_unstemmed | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE |
| title_short | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE |
| title_sort | up to date antiplatelet therapy in patients with high risk of thrombotic events and real clinical practice |
| topic | антиагреганты клопидогрел оригинальный лекарственный препарат воспроизведенный лекарственный препарат двойная антиагрегантная терапия |
| url | http://www.rpcardio.ru/jour/article/view/540 |
| work_keys_str_mv | AT syumartsevich uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT vpvoronina uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT mlginzburg uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT npkutishenko uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT yunpolyanskaya uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT tgkheliya uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT ammalysheva uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT sntolpygina uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT vskutuzova uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT eagofman uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice AT addeev uptodateantiplatelettherapyinpatientswithhighriskofthromboticeventsandrealclinicalpractice |